An update from BiomX ( (PHGE) ) is now available.
On March 31, 2025, BiomX Inc. announced positive results from its Phase 2 trial of BX211 for treating Diabetic Foot Osteomyelitis (DFO) associated with Staphylococcus aureus. The trial demonstrated that BX211 was safe, well-tolerated, and produced statistically significant reductions in ulcer size and depth compared to placebo. These findings highlight the potential of phage therapy in addressing serious bacterial infections and reducing the need for amputations in diabetic patients. Following these results, BiomX plans to proceed with a Phase 2/3 trial pending FDA feedback.
More about BiomX
BiomX is a clinical-stage company focused on developing natural and engineered phage therapies that target specific pathogenic bacteria. The company is advancing personalized phage treatments designed to combat harmful bacteria, with a particular focus on addressing unmet needs in chronic infections and antibiotic-resistant conditions.
YTD Price Performance: -27.52%
Average Trading Volume: 76,716
Technical Sentiment Signal: Buy
Current Market Cap: $14.22M
For a thorough assessment of PHGE stock, go to TipRanks’ Stock Analysis page.